BRPI1010975A2 - métodos para preparar nalmefeno de naltrexona em uma reação de wittig, e para isolar o nalmefeno, e, composição farmacêutica - Google Patents

métodos para preparar nalmefeno de naltrexona em uma reação de wittig, e para isolar o nalmefeno, e, composição farmacêutica

Info

Publication number
BRPI1010975A2
BRPI1010975A2 BRPI1010975A BRPI1010975A BRPI1010975A2 BR PI1010975 A2 BRPI1010975 A2 BR PI1010975A2 BR PI1010975 A BRPI1010975 A BR PI1010975A BR PI1010975 A BRPI1010975 A BR PI1010975A BR PI1010975 A2 BRPI1010975 A2 BR PI1010975A2
Authority
BR
Brazil
Prior art keywords
nalmefene
isolate
methods
pharmaceutical composition
wittig reaction
Prior art date
Application number
BRPI1010975A
Other languages
English (en)
Inventor
Carla De Faveri
Mauro Casarin
Michele Brusegan
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1010975(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BRPI1010975A2 publication Critical patent/BRPI1010975A2/pt
Publication of BRPI1010975B1 publication Critical patent/BRPI1010975B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI1010975-7A 2009-05-25 2010-05-21 Métodos para preparar nalmefeno a partir de naltrexona em uma reação de wittig e para isolar o nalmefeno BRPI1010975B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900650 2009-05-25
DKPA200900650 2009-05-25
PCT/DK2010/050110 WO2010136039A1 (en) 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone

Publications (2)

Publication Number Publication Date
BRPI1010975A2 true BRPI1010975A2 (pt) 2015-10-20
BRPI1010975B1 BRPI1010975B1 (pt) 2021-08-24

Family

ID=43222172

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010975-7A BRPI1010975B1 (pt) 2009-05-25 2010-05-21 Métodos para preparar nalmefeno a partir de naltrexona em uma reação de wittig e para isolar o nalmefeno

Country Status (35)

Country Link
US (1) US8598352B2 (pt)
EP (1) EP2435439B8 (pt)
JP (1) JP5794980B2 (pt)
KR (1) KR101716522B1 (pt)
CN (1) CN102459276B (pt)
AR (1) AR076891A1 (pt)
AU (1) AU2010252392B2 (pt)
BR (1) BRPI1010975B1 (pt)
CA (1) CA2763093C (pt)
CL (1) CL2011002974A1 (pt)
CO (1) CO6470832A2 (pt)
CR (1) CR20110612A (pt)
DK (1) DK2435439T3 (pt)
DO (1) DOP2011000362A (pt)
EA (1) EA019331B1 (pt)
ES (1) ES2564006T3 (pt)
GE (1) GEP20146190B (pt)
HR (1) HRP20160110T1 (pt)
HU (1) HUE026892T2 (pt)
IL (1) IL216422A (pt)
MA (1) MA33368B1 (pt)
ME (1) ME02622B (pt)
MX (1) MX2011012502A (pt)
MY (1) MY158251A (pt)
NZ (1) NZ596988A (pt)
PL (1) PL2435439T3 (pt)
RS (1) RS54599B1 (pt)
SG (1) SG176205A1 (pt)
SI (1) SI2435439T1 (pt)
SM (1) SMT201600061B (pt)
TN (1) TN2011000590A1 (pt)
TW (1) TWI469985B (pt)
UA (1) UA106752C2 (pt)
WO (1) WO2010136039A1 (pt)
ZA (1) ZA201108659B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2580201B1 (en) 2010-06-11 2017-08-02 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
DK2635586T3 (en) 2010-11-05 2017-03-27 H Lundbeck As PROCEDURE FOR THE PREPARATION OF NALTREXON
CN103012416B (zh) * 2011-09-28 2015-07-01 辽宁海思科制药有限公司 一种盐酸纳美芬的制备方法
TWI560170B (en) 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CN102584840A (zh) * 2011-12-28 2012-07-18 南京优科生物医药有限公司 一种制备纳美芬化合物的方法
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN103204859B (zh) * 2013-04-25 2015-12-02 四川海思科制药有限公司 一种盐酸纳美芬化合物及其制备方法
AR096851A1 (es) * 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
JP6448645B2 (ja) 2013-12-20 2019-01-09 ハー・ルンドベック・アクチエゼルスカベット メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
AU2015250611A1 (en) 2014-04-22 2016-11-24 H. Lundbeck A/S Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
CN104513251A (zh) * 2014-11-28 2015-04-15 安徽悦康凯悦制药有限公司 一种盐酸纳美芬的制备方法
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2712232C1 (ru) * 2018-10-05 2020-01-27 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Улучшенный способ получения налмефена из налтрексона
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
JP2023548356A (ja) 2020-11-02 2023-11-16 ローズ テクノロジーズ ノルオキシモルホンを精製するための方法
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法
CN119080788A (zh) * 2024-08-19 2024-12-06 南京海鲸药业股份有限公司 一种盐酸纳美芬杂质的去除监控系统及去除方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4322426A (en) 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US7687646B2 (en) 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene

Also Published As

Publication number Publication date
EP2435439A1 (en) 2012-04-04
CA2763093A1 (en) 2010-12-02
ES2564006T3 (es) 2016-03-17
CN102459276B (zh) 2016-09-21
EP2435439B1 (en) 2016-01-06
ME02622B (me) 2017-06-20
MX2011012502A (es) 2011-12-12
CA2763093C (en) 2017-03-07
RS54599B1 (sr) 2016-08-31
EA019331B1 (ru) 2014-02-28
JP5794980B2 (ja) 2015-10-14
CR20110612A (es) 2012-02-22
AU2010252392A1 (en) 2012-01-12
MY158251A (en) 2016-09-30
WO2010136039A1 (en) 2010-12-02
CL2011002974A1 (es) 2012-04-13
KR20120023704A (ko) 2012-03-13
DOP2011000362A (es) 2012-07-15
AU2010252392B2 (en) 2014-10-23
HRP20160110T1 (hr) 2016-03-11
TW201043634A (en) 2010-12-16
JP2012527489A (ja) 2012-11-08
US20120123123A1 (en) 2012-05-17
CN102459276A (zh) 2012-05-16
MA33368B1 (fr) 2012-06-01
TN2011000590A1 (en) 2013-05-24
SG176205A1 (en) 2011-12-29
US8598352B2 (en) 2013-12-03
DK2435439T3 (en) 2016-02-29
SMT201600061B (it) 2016-07-01
ZA201108659B (en) 2013-02-27
BRPI1010975B1 (pt) 2021-08-24
PL2435439T3 (pl) 2016-05-31
EP2435439B8 (en) 2016-05-18
SI2435439T1 (sl) 2016-06-30
EA201171461A1 (ru) 2012-05-30
KR101716522B1 (ko) 2017-03-14
CO6470832A2 (es) 2012-06-29
UA106752C2 (uk) 2014-10-10
NZ596988A (en) 2013-03-28
IL216422A (en) 2015-06-30
IL216422A0 (en) 2012-02-29
TWI469985B (zh) 2015-01-21
GEP20146190B (en) 2014-11-10
HUE026892T2 (en) 2016-07-28
AR076891A1 (es) 2011-07-13

Similar Documents

Publication Publication Date Title
BRPI1010975A2 (pt) métodos para preparar nalmefeno de naltrexona em uma reação de wittig, e para isolar o nalmefeno, e, composição farmacêutica
BRPI0912106A2 (pt) probióticos para melhorar a microbiota intestinal
ZA201107776B (en) Pharmaceutical composition
IL245326B (en) pharmaceutical preparation
IL208328A0 (en) Methods to produce strechable products
BRPI0914326A2 (pt) método para formar uma corrente de oxigênio quente
BRPI0817547A2 (pt) Método para realizar pirólise
LT2619182T (lt) Farmacinė kompozicija
IL225457A0 (en) Pharmaceutical composition
EP2379077A4 (en) PHARMACEUTICAL COMPOSITION
IL216256A0 (en) A pharmaceutical composition
ZA201207839B (en) Pharmaceutical composition comprising a pyrimidineone derivative
PT2429502T (pt) Método e composição para melhorar a absorção de aspirina
PT2579858E (pt) Composição farmacêutica que contém ivabradina
HU0900072D0 (en) Transdermal pharmaceutical compositions
ZA201304633B (en) A pharmaceutical composition
EP2552665A4 (en) EXTRUSION PROFILE REPLICATION
GB201010453D0 (en) Pharmaceutical composition
GB0902595D0 (en) Improvements to building blocks
BRPI1014803A2 (pt) dispositivo para perfilação de uma peça a ser trabalhada
GB201001911D0 (en) Pharmaceutical composition
GB0919650D0 (en) Pharmaceutical composition
PL2561504T3 (pl) Oświetlona fasada
ZA201201003B (en) A pharmaceutical composition
GB0904615D0 (en) Computer to move objects

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 489/08

Ipc: C07D 489/08 (2006.01), A61P 3/04 (2006.01), A61K 3

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.